Abstracts tagged "citrullination"

Abstract Number: 452 • 2014 ACR/ARHP Annual Meeting
The Use of Multiplex Bead Array to Follow the Effect of Rituximab on IgG and IgA Serum Autoantibody Responses to Citrullinated Epitopes in Patients with Rheumatoid Arthritis
Geraldine Cambridge¹, Lauren J. Lahey², Maria J. Leandro¹, William H. Robinson² and Jeremy Sokolove², ¹Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ²VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA
Background/Purpose The majority of patients with established Rheumatoid arthritis (RA) have autoantibodies against the Fc of IgG (Rheumatoid factors-RhF) and to citrullinated protein antigens (ACPAs).…
Abstract Number: 433 • 2014 ACR/ARHP Annual Meeting
Bronchiectasis: A Model for Chronic Bacterial Infection Inducing Autoimmunity in Rheumatoid Arthritis
Anne-Marie Quirke¹, Elizabeth Perry², Alison Cartwright¹, Clive Kelly³, Anthony De Sozya^4,5, Paul Eggleton⁶, David Hutchinson² and Patrick Venables⁷, ¹Kennedy Institute, Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Rheumatology, Royal Cornwall Hospital, Truro, United Kingdom, ³Rheumatology, Queen Elizabeth Hospital, Gateshead, United Kingdom, ⁴Institute for Cellular Medicine, Newcastle University, Newcastle, United Kingdom, ⁵Sir William Leech Centre, The Freeman Hospital, Newcastle, United Kingdom, ⁶Medical School, University of Exeter, Exeter, United Kingdom, ⁷Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom
Background/Purpose Anti-citrullinated peptide antibodies (ACPA) are associated with smoking in patients with rheumatoid arthritis (RA). Bronchiectasis (BR), which tends to occur in non-smokers, has been…
Abstract Number: 361 • 2014 ACR/ARHP Annual Meeting
Citrullinated 14-3-3η Antibodies Are Specific for Early and Established RA and Are Complementary to ACPA
Anthony Marotta¹, Dirkjan van Schaardenburg², Gilles Boire³, Désirée van der Heijde⁴, Robert Landewé⁵, Maarten Boers⁶, C.F. Allaart⁷, Mairead Murphy⁸, Samina Turk⁹, Vivian P. Bykerk¹⁰, Edward Keystone¹¹, Katherine A. Siminovitch¹¹ and Walter P. Maksymowych¹², ¹1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada, ²Dr Jan van Breemenstraat 2, Reade, Amsterdam, Netherlands, ³Rheumatology Division, CHUS - Sherbrooke University, Sherbrooke, QC, Canada, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁶Deapartment of Epidemiology and Biostatistics, Jan van Breemen Research Institute/Reade, Amsterdam, Netherlands, ⁷Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁸Augurex Life Sciences Corp., North Vancouver, BC, Canada, ⁹Reade, Amsterdam, Netherlands, ¹⁰Divison of Rheumatology, Hospital for Special Surgery, New York, NY, ¹¹Mount Sinai Hospital, Toronto, ON, Canada, ¹²Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose Citrullination is a post-translational modification whereby arginine (Arg) is deiminated by PAD enzymes to form citrulline (Cit). In RA, current ACPA assays measure the…
Abstract Number: 359 • 2014 ACR/ARHP Annual Meeting
14-3-3η Cit:Arg Antibody Ratios: Are We Overlooking the Prognostic Utility of Citrullinated Antibodies By Only Looking at Titers?
Anthony Marotta¹, Samina Turk², Mairead Murphy³, Walter P. Maksymowych⁴ and Dirkjan van Schaardenburg⁵, ¹1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada, ²Reade, Amsterdam, Netherlands, ³Augurex Life Sciences Corp., North Vancouver, BC, Canada, ⁴Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁵Dr Jan van Breemenstraat 2, Reade, Amsterdam, Netherlands
Background/Purpose Citrullination is a post-translational modification whereby arginine (Arg) is deiminated by PAD enzymes to form citrulline (Cit). In RA, there are auto-antibodies (AAb) to…
Abstract Number: 2426 • 2013 ACR/ARHP Annual Meeting
Signaling Abnormalities In Neutrophil Granulocytes Of Rheumatoid Arthritis Patients Are Associated With Increased Extracellular Trap Formation and Provide a Basis For The Induction Of Anti-Citrullinated Peptide Antibodies
Chanchal Sur Chowdhury¹, Stavros Giaglis^2,3, Ulrich A. Walker⁴, Andreas Buser⁵, Paul Hasler² and Sinuhe Hahn⁶, ¹Dept. of Biomedicine, Laboratory of Prenatal Diagnostics, University Hospital Basel, Basel, Switzerland, ²Dept. of Rheumatology, Kantonsspital Aarau, Aarau, Switzerland, ³Dept. of Biomedicine, Laboratory of Prenatal Madicine, University Hospital Basel, Basel, Switzerland, ⁴Department of Rheumatology, University Hospital Basel, Basel, Switzerland, Basel, Switzerland, ⁵Division of Hematology; Swiss Red Cross Blood Transfusion Centre, University Hospital Basel, Basel, Switzerland, ⁶Dept. of Biomedicine, Laboratory for Prenatal Medicine, University Hospital Basel, Basel, Switzerland
Background/Purpose: Rheumatoid arthritis (RA) is often associated with anti-citrullinated peptide antibodies (ACPAs) in the serum. While ACPAs have been associated with increased inflammation, joint destruction…
Abstract Number: 1399 • 2013 ACR/ARHP Annual Meeting
Citrullinated Proteoglycan (Aggrecan) Present In Human Cartilage Is Recognized By Serum Antibodies From Rheumatoid Arthritis Patients
Timea Ocsko¹, Beata Tryniszewska¹, Andras Vida¹, Janos Gal², Gyorgyi Soos², Zoltan Szekanecz³, Tibor A. Rauch¹, Joshua Jacobs¹, Tibor T. Glant¹ and Katalin Mikecz¹, ¹Orthopedic Surgery, Rush University Medical Center, Chicago, IL, ²Rheumatology, Bacs-Kiskun County Hospital, Kecskemet, Hungary, ³Rheumatology, University of Debrecen Medical and Health Sciences Center, Debrecen, Hungary
Background/Purpose: Citrullination is a post-translational protein modification, where arginine (Arg) is converted to citrulline (Cit) by peptidyl arginine deiminases (PADI). The presence of anti-citrullinated protein…
Abstract Number: 813 • 2013 ACR/ARHP Annual Meeting
Citrulline Specific CD4+ T Cells Exhibit a Th1 Memory Phenotype In Rheumatoid Arthritis Subjects and Their Ex Vivo Frequency Is Influenced By Both Disease Duration and Biologic Therapy
Eddie James¹, Mary Rieck², Jennifer Pieper³, John Gebe⁴, Betty Yue⁴, Megan Tatum⁵, Charlotta Sandin⁶, Lars Klareskog⁷, Vivianne Malmström⁸ and Jane Buckner⁹, ¹Benaroya Research Institute, Seattle, WA, ²Translational Research Program, Benaroya Research Institute, Seattle, WA, ³Department of Medicine, Karolinska Institutet, Rheumatology Unit, Stockholm, Sweden, ⁴Diabetes Research Program, Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁵Translational Research Program, Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁶Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ⁷Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁸Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁹Translational Research Program, Benaroya Research Institute, Seattle, WA 98101, USA,, Seattle, WA
Background/Purpose: Rheumatoid arthritis is thought to be a T cell mediated disease, based on its strong association with HLA class II alleles, clinical responsiveness to…
Abstract Number: 774 • 2013 ACR/ARHP Annual Meeting
Citrullination Of ENA-78/CXCL5 Changes Its Receptor Affinity From CXCR2 To CXCR1 and Induces Monocyte Migration
Ken Yoshida¹, Alisa E. Koch^1,2, Ray A. Ohara³, Phillip L. Campbell¹, M. Asif Amin¹, David A. Fox¹ and Jeffrey H. Ruth⁴, ¹Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, ²VA Medical Service, Ann Arbor, MI, ³University of Michigan Medical School, Ann Arbor, MI, ⁴Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: We previously showed that citrullinated epithelial-derived neutrophil-activating peptide 78/CXCL5 (citENA-78/CXCL5) was significantly higher in rheumatoid arthritis (RA) synovial fluids (SFs) compared to osteoarthritis (OA)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].